Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 8/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375899 | 1.00 | MTNR1B (0.52) | MTNR1BMTNR1ASSTR2ROCK2MELK | |
| SCHEMBL3372837 | 0.84 | ROCK2 (0.50) | MTNR1BMTNR1AROCK2 | |
| SCHEMBL3372840 | 0.84 | ROCK2 (0.50) | MTNR1BMTNR1AROCK2 | |
| SCHEMBL3452803 | 0.84 | ROCK2 (0.50) | MTNR1BMTNR1AROCK2 | |
| SCHEMBL3452807 | 0.84 | ROCK2 (0.50) | MTNR1BMTNR1AROCK2 | |
| SCHEMBL3375559 | 0.80 | MTNR1B (0.50) | MTNR1BMTNR1A | |
| SCHEMBL3375560 | 0.80 | MTNR1B (0.50) | MTNR1BMTNR1A | |
| SCHEMBL4779104 | 0.79 | MTNR1B (0.44) | MTNR1BMTNR1ASSTR2MELKAXL | |
| SCHEMBL3779200 | 0.73 | SLC2A1 (0.47) | MTNR1BMTNR1ASSTR2 | |
| SCHEMBL14400285 | 0.72 | MTNR1B (0.64) | MTNR1BMTNR1APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7820655-B2 | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1987040-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093963-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | RBPJ, RXRA, MRPL21 | MTNR1B 57/4885MTNR1A 50/4885SSTR2 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.